Search results
Gilead Sciences Unusual Options Activity For May 06 - Gilead Sciences (NASDAQ:GILD)
Benzinga· 1 day agoLoading... Loading... Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead</ ...
Choreo LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 6 days agoChoreo LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 53.6% in the fourth quarter, according to its most recent ...
Forbes Has Listed Gilead as One of America’s Best
3BL CSRwire· 2 days agoForbes has listed Gilead as one of America’s Best Employers for Diversity. Gilead Sciences, Inc. is a research-based biopharmaceutical company that...
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Zacks via Yahoo Finance· 5 days agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
Gilead Sciences, Inc. [NASDAQ: GILD] Sees Decrease in Stock Value – Knox Daily
Knox Daily· 5 days agoInvestors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Gilead Sciences, Inc. shares valued at $368,790 were ...
Gilead Sciences, Inc. (GILD): Be Patient, You Will Learn – Stocks Register
Stocks Register· 5 days agoGilead Sciences, Inc. (NASDAQ:GILD) at last check was buoying at $64.49 on Friday, May 03, with a fall of -1.29% from its closing price on previous day.
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
InvestorPlace· 1 day agoIf you really want to maximize your return potential, then acquiring stocks near 52-week lows could...
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Zacks via Yahoo Finance· 18 hours agoAfter a lull of almost two years, pharma and pharma/biotech bigwigs are now looking to bolster their...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoNew York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead
Kyverna Therapeutics Inc. (KYTX) Stock Showcases
NewsHeater· 6 days agoThe volatility ratio for the week is 9.90%, and the volatility levels for the past 30 days are at 7.63% for KYTX. The simple moving average for the past 20 days is -18.29% for KYTX’s stock, ...
